Dosing Variability and Clinical Outcomes of Oxybutynin: A Pediatric Cohort of Patients With Neurogenic Bladder.

Document Type


Publication Date

Summer 2022


DOI: 10.46292/sci21-00091


Background: Despite the therapeutic advancements of the last several decades, neurogenic bladder remains a significant source of morbidity for patients with a spinal pathology. Oxybutynin is a mainstay of treatment in pediatric populations despite significant side effects and highly variable bioavailability.

Objectives: To characterize the use of oxybutynin in a cohort of pediatric patients with neurogenic bladder.

Methods: Retrospective data were collected of dosing, drug interactions, and urodynamics parameters in the 100 consecutive patients in a spinal differences clinic who had an appointment between October 7, 2015, and December 30, 2015. In addition to descriptive statistics, a linear regression model of oxybutynin dose versus age and sex was developed to examine the impact of age on dosing variability.

Results: One hundred patients (52% female) with a median age of 6.8 years were included. The median daily dose of oxybutynin was 0.36 mg/kg (interquartile range, 0.28-0.54 mg/kg). Of the 48 patients with a recent urodynamics study, 13 had a detrusor leak point pressure (DLPP) greater than the typical cutoff of 40 cm H2O, indicating a need for management escalation. However, of these 13 patients, 38% were already on or exceeding oxybutynin's maximum recommended dose.

Conclusion: The wide dosing variability and high DLPPs despite maximal dosing indicate a need for further investigation of oxybutynin's bioavailability in this population compared to its side effects and clinical outcomes. If variability in response to the medication is due to differences in bioavailability, then a precision-dosing model based on patient genomics could be developed for oxybutynin.

Journal Title

Top Spinal Cord Inj Rehabil





First Page


Last Page


MeSH Keywords

Child; Female; Humans; Male; Mandelic Acids; Retrospective Studies; Spinal Cord Injuries; Urinary Bladder, Neurogenic; Urodynamics


cholinergic antagonists; neurogenic; pediatrics; spinal dysraphism; urinary bladder


Grant support

Financial Support This research was supported by National Institute of Health grant 1K12HD093427.

Library Record